Fluconazole

Research use only, not for human use.

Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS.

Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. (In Vitro):Fluconazole inhibits 4 species ofAspergillus fumigatus with the IC50s of 23.9-43.5 μg/mL. Fluconazole (0.20 μg/mL) inhibits significantly the mycelial-phase growth and germ tube elongation of C. albicans in a medium supplemented with serum.Fluconazole is a triazole antifungal agent that has been available for the treatment of infections due to Candida, Cryptococcus. The MIC90 is highest for C. krusei (MIC ≥ 64 μg/mL) and C. glabrata (MIC, 32 μg/mL) and is ≤2 μg/mL for C. albicans (0.5 μg/mL), C. parapsilosis (2 μg/mL), C. tropicalis (2 μg/mL), C. lusitaniae (2 μg/mL), and C. kefyr (0.5 μg/mL).Fluconazole (0.1-50.0 μg/mL) damages the fungal cells and reduces their viability.(In Vivo):Fluconazole ( 0, 0.5, 1, 2.5, 5, 7.5, and 10 mg/kg; administered intraperitoneally (i.p.) as a single dose) results in a 50% reduction in fungal densities (ED50) of 4.87 mg/kg in a murine model of systemic candidiasis. Fluconazole exhibits terminal elimination half-life of 2.4 h) following i.p.

Cell Viability Assay Cell Line:C.albicans yeast cells (strain ATCC 26310 and strain TW) Concentration:0.1, 0.5, 5.0, 50.0 μg/mL Incubation Time:24 hours Result:The MICs against both strains were 0.5 μg/mL.

Animal Model:Female NYLAR mice (weight, 18 to 20 g; infected intravenously with C. albicans blastoconidia)Dosage:5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis) Administration:Given i.p. as a single dose Result:T1/2=2.4 h

UK 49858

Microbiology/Virology

Antifection

14-α Demethylase

Infection

——

86386-73-4

306.27

C13H12F2N6O

>98% (HPLC)

Ethanol: 61 mg/mL (199.17 mM); DMSO: 61 mg/mL (199.17 mM)

OC(CN1N=CN=C1)(C2=CC=C(F)C=C2F)CN3N=CN=C3

2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol

(-20℃)

With Ice Pack

≥ 2 years